Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas von Bubnoff

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
IAVI Report : Newsletter on International AIDS Vaccine Research|March 16, 2010
Looking for the perfect challengeAndreas von Bubnoff
IAVI Report : Newsletter on International AIDS Vaccine Research|March 10, 2010
Apobec3 may restrict retroviral infection by controlling antibody responseAndreas von Bubnoff
IAVI Report : Newsletter on International AIDS Vaccine Research|March 10, 2010
Mighty mice. Scientists are still improving the humanized mouse model but are optimistic about its future role in evaluating AIDS vaccine candidatesAndreas von Bubnoff
IAVI Report : Newsletter on International AIDS Vaccine Research|March 11, 2010
Elite controllers found to have more lethal CD8+ T cellsAndreas von Bubnoff
IAVI Report : Newsletter on International AIDS Vaccine Research|May 26, 2011
Phase I trial of novel HIV vaccine candidate prime-boost regimen starts in AfricaAndreas von Bubnoff
IAVI Report : Newsletter on International AIDS Vaccine Research|December 18, 2010
Phase I trial of adenovirus-based prime-boost regimen begins in BostonAndreas von Bubnoff
IAVI Report : Newsletter on International AIDS Vaccine Research|March 27, 2012
Adenovirus vectors: promise and possible pitfallsAndreas von Bubnoff
IAVI Report : Newsletter on International AIDS Vaccine Research|March 27, 2012
Researchers analyze CD8+ T cell types in unprecedented detailAndreas von Bubnoff
IAVI Report : Newsletter on International AIDS Vaccine Research|February 22, 2012
A gut response to vaccinesAndreas von Bubnoff
IAVI Report : Newsletter on International AIDS Vaccine Research|August 4, 2011
Researchers identify host restriction factor that is target of VpxAndreas von Bubnoff
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
IAVI Report : Newsletter on International AIDS Vaccine Research|March 16, 2010
Looking for the perfect challengeAndreas von Bubnoff
IAVI Report : Newsletter on International AIDS Vaccine Research|March 10, 2010
Apobec3 may restrict retroviral infection by controlling antibody responseAndreas von Bubnoff
IAVI Report : Newsletter on International AIDS Vaccine Research|March 10, 2010
Mighty mice. Scientists are still improving the humanized mouse model but are optimistic about its future role in evaluating AIDS vaccine candidatesAndreas von Bubnoff
IAVI Report : Newsletter on International AIDS Vaccine Research|March 11, 2010
Elite controllers found to have more lethal CD8+ T cellsAndreas von Bubnoff
IAVI Report : Newsletter on International AIDS Vaccine Research|May 26, 2011
Phase I trial of novel HIV vaccine candidate prime-boost regimen starts in AfricaAndreas von Bubnoff
IAVI Report : Newsletter on International AIDS Vaccine Research|December 18, 2010
Phase I trial of adenovirus-based prime-boost regimen begins in BostonAndreas von Bubnoff
IAVI Report : Newsletter on International AIDS Vaccine Research|March 27, 2012
Adenovirus vectors: promise and possible pitfallsAndreas von Bubnoff
IAVI Report : Newsletter on International AIDS Vaccine Research|March 27, 2012
Researchers analyze CD8+ T cell types in unprecedented detailAndreas von Bubnoff
IAVI Report : Newsletter on International AIDS Vaccine Research|February 22, 2012
A gut response to vaccinesAndreas von Bubnoff
IAVI Report : Newsletter on International AIDS Vaccine Research|August 4, 2011
Researchers identify host restriction factor that is target of VpxAndreas von Bubnoff
Pageof 11